提高吸入粉雾剂的有效沉积率的研究进展  

Study on improving effective deposition of DPIs by various ways

作　　者：韩英 孙亮 李岩峰 周业芳 何光杰 HAN Ying;SUN Liang;LI Yanfeng;ZHOU Yefang;HE Guangjie(Tianjin Kinnovata Pharmaceutical Co.,Ltd.,Tianjin 300457,China;Tianjin Tiayao Pharmceutical Group Co.,Ltd.,Tianjin 300457,China;Tianjin Pharmaceuticals Research Institute Co.,Ltd.,Tianjin 300457,China;Tianjin Enterprise Key Laboratory of Dry Powder Inhalation,Tianjin 300457,China)

机构地区：[1]天津信诺制药有限公司,天津300457 [2]天津药业集团有限公司,天津300457 [3]天津药业研究院有限公司,天津300457 [4]天津市粉雾吸入药物企业重点实验室,天津300457

出　　处：《药物评价研究》2019年第12期2329-2331,共3页Drug Evaluation Research

摘　　要：全球已上市品种体外检测数据显示,吸入粉雾剂相比气雾剂和吸入溶液肺部沉积率偏低,为药物总量的10%~40%,进入肺部的药物占药物总量的20%~30%,药物利用率较低。旨在讨论通过多种途径提高吸入粉雾剂的有效沉积率,提升药物的治疗效果。The in vitro test data of global listed varieties shows that the lung deposition of DPIs is lower than that of pMDI and inhaled solution, which is about 10%-40% of the total amount of drugs, and the drugs that actually enter to the lung account for about 20%-30%. The drug utilization rate is low. The purpose of this paper is to explore various ways to improve the effective deposition of DPIs, so as to improve the therapeutic effect of drugs.

关 键 词：吸入粉雾剂 有效沉积率 微细粒子 体内外一致性 

分 类 号：R944[医药卫生—药剂学]